# FHL1

## Overview
The FHL1 gene encodes the protein four and a half LIM domains 1, which is a crucial component in muscle development and function. This protein is categorized as a cytoskeletal protein due to its involvement in structural and regulatory roles within muscle cells. FHL1 is characterized by its unique structure, comprising four complete LIM domains and an additional half-LIM domain, which facilitate protein-protein interactions essential for muscle differentiation and sarcomere assembly (Emmanuele2014Fhl1; Schessl2008Proteomic). The gene is predominantly expressed in skeletal and cardiac muscle tissues, where the protein localizes to the sarcomere, contributing to muscle growth, differentiation, and biomechanical stress responses (Emmanuele2014Fhl1). Mutations in FHL1 are linked to several muscular disorders, including X-linked myopathy and Emery-Dreifuss muscular dystrophy, underscoring its clinical significance in muscle pathology (Bertrand2014199th; Gueneau2009Mutations).

## Structure
The FHL1 protein is characterized by its domain structure, which includes four complete LIM domains and an additional N-terminal half-LIM domain. LIM domains are cysteine-rich, tandem zinc-finger motifs that facilitate protein-protein interactions (Emmanuele2014Fhl1; Schessl2008Proteomic). These domains are crucial for the protein's function, particularly in muscle development and function, as they allow FHL1 to interact with other proteins involved in muscle growth and differentiation (Emmanuele2014Fhl1).

FHL1 is expressed in skeletal and cardiac muscle, where it localizes to the sarcomere, specifically at the I-band and M-line, playing a role in sarcomere assembly and biomechanical stress response (Emmanuele2014Fhl1). The protein's structure is highly conserved across species, indicating its phylogenetic importance (Krempler2000Isolation).

FHL1 has several isoforms resulting from alternative splicing, including FHL1A, FHL1B, and FHL1C, each with distinct domain compositions and functions. FHL1A is the full-length protein, while FHL1B and FHL1C have variations in their LIM domain structures and additional functional regions (Schessl2008Proteomic). These isoforms exhibit tissue-specific expression patterns, particularly in muscle tissues (Krempler2000Isolation). The presence of these isoforms suggests a complex regulation of FHL1's role in muscle physiology.

## Function
The FHL1 gene encodes a protein that plays a significant role in various cellular processes, particularly in muscle cells. FHL1 is characterized by its four-and-a-half highly conserved LIM domains, which serve as a modular protein binding interface, facilitating protein-protein interactions (Wang2013Identification). In skeletal muscle, FHL1 is involved in sarcomere assembly, muscle differentiation, growth, and responses to biomechanical stress, highlighting its importance in maintaining muscle cellular structure and function (Wang2013Identification). 

FHL1 is also implicated in cardiac muscle function, where it is part of a complex within the cardiomyocyte sarcomere that mediates hypertrophic biomechanical stress responses. It interacts with the N2B region of titin, a component of the sarcomere, and modulates cardiac MAPK activation, specifically affecting ERK1/2 phosphorylation (Sheikh2008An). This interaction is crucial for diastolic function and biomechanical stress responses, suggesting FHL1's role in maintaining cardiac muscle function and structure (Sheikh2008An).

In addition to its role in muscle tissues, FHL1 is involved in cytoskeletal scaffolding and regulation of transcription factors, contributing to muscle growth, differentiation, and sarcomere assembly (Schessl2008Proteomic).

## Clinical Significance
Mutations in the FHL1 gene are associated with a range of muscular disorders, primarily affecting skeletal and cardiac muscles. One such condition is X-linked myopathy with postural muscle atrophy (XMPMA), characterized by tendon contractures, gait problems, and muscle hypertrophy in males. This condition is linked to the p.C224W mutation, which affects the 4th LIM domain of FHL1A and FHL1B, leading to reduced protein expression in muscle biopsies (Bertrand2014199th).

FHL1 mutations also cause Emery-Dreifuss muscular dystrophy (EDMD), which presents with myopathy, joint contractures, and cardiomyopathy. Some male relatives with these mutations may exhibit isolated cardiac disease, while heterozygous female carriers can be asymptomatic or have mild symptoms (Gueneau2009Mutations).

Another condition associated with FHL1 mutations is reducing body myopathy (RBM), characterized by intracytoplasmic inclusions in muscle tissues. These mutations often affect conserved residues in the second LIM domain, disrupting zinc binding and leading to a dominant-negative effect (Schessl2008Proteomic).

Hypertrophic cardiomyopathy (HCM) is another disorder linked to FHL1 mutations, featuring spongy structures in the left ventricular myocardium and impaired cardiac function. The preserved FHL1C isoform interacts with the potassium channel Kv1.5, which is associated with sudden cardiac death and atrial fibrillation (Bertrand2014199th).

## Interactions
FHL1, a protein characterized by its four-and-a-half LIM domains, is involved in various protein-protein interactions crucial for muscle development and function. It interacts with gamma-actin (Actg1) and non-muscle myosin IIB (Myh10), forming a complex that plays a significant role in skeletal muscle differentiation and function. These interactions were identified using immunoprecipitation and mass spectrometry techniques, and their presence was confirmed in both embryonic and adult skeletal muscle tissues (Wang2013Identification).

FHL1 is also implicated in reducing body myopathy (RBM), where it forms intracytoplasmic inclusions in muscle biopsies. These inclusions are enriched with FHL1 and other proteins such as desmin and ubiquitin, indicating a potential interaction or co-localization in pathological conditions (Schessl2008Proteomic). Mutations in FHL1, particularly in its LIM domains, can lead to the formation of aggresome-like inclusions that trap both mutant and wild-type FHL1, as well as other muscle proteins like MyBP-C, dystrophin, and LAMP1, suggesting a dominant-negative effect (Schessl2008Proteomic). These interactions highlight FHL1's role in muscle pathology and its potential impact on muscle function.


## References


[1. (Bertrand2014199th) Anne T. Bertrand, Carsten G. Bönnemann, and Gisèle Bonne. 199th enmc international workshop: fhl1 related myopathies, june 7–9, 2013, naarden, the netherlands. Neuromuscular Disorders, 24(5):453–462, May 2014. URL: http://dx.doi.org/10.1016/j.nmd.2014.02.002, doi:10.1016/j.nmd.2014.02.002. This article has 11 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.nmd.2014.02.002)

[2. (Wang2013Identification) Lili Wang, Jianing Miao, Lianyong Li, Di Wu, Yi Zhang, Zhaohong Peng, Lijun Zhang, Zhengwei Yuan, and Kailai Sun. Identification of an fhl1 protein complex containing gamma-actin and non-muscle myosin iib by analysis of protein-protein interactions. PLoS ONE, 8(11):e79551, November 2013. URL: http://dx.doi.org/10.1371/journal.pone.0079551, doi:10.1371/journal.pone.0079551. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0079551)

[3. (Emmanuele2014Fhl1) Valentina Emmanuele, Akatsuki Kubota, Beatriz Garcia-Diaz, Caterina Garone, Hasan O. Akman, Daniel Sánchez-Gutiérrez, Luis M. Escudero, Shingo Kariya, Shunichi Homma, Kurenai Tanji, Catarina M. Quinzii, and Michio Hirano. Fhl1 w122s causes loss of protein function and late-onset mild myopathy. Human Molecular Genetics, 24(3):714–726, September 2014. URL: http://dx.doi.org/10.1093/hmg/ddu490, doi:10.1093/hmg/ddu490. This article has 13 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/ddu490)

[4. (Schessl2008Proteomic) Joachim Schessl, Yaqun Zou, Meagan J. McGrath, Belinda S. Cowling, Baijayanta Maiti, Steven S. Chin, Caroline Sewry, Roberta Battini, Ying Hu, Denny L. Cottle, Michael Rosenblatt, Lynn Spruce, Arupa Ganguly, Janbernd Kirschner, Alexander R. Judkins, Jeffrey A. Golden, Hans-Hilmar Goebel, Francesco Muntoni, Kevin M. Flanigan, Christina A. Mitchell, and Carsten G. Bönnemann. Proteomic identification of fhl1 as the protein mutated in human reducing body myopathy. Journal of Clinical Investigation, February 2008. URL: http://dx.doi.org/10.1172/jci34450, doi:10.1172/jci34450. This article has 15 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci34450)

[5. (Krempler2000Isolation) A. Krempler, S. Kollers, R. Fries, and B. Brenig. Isolation and characterization of a new fhl1 variant (fhl1c) from porcine skeletal muscle. Cytogenetic and Genome Research, 90(1–2):106–114, 2000. URL: http://dx.doi.org/10.1159/000015643, doi:10.1159/000015643. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000015643)

[6. (Sheikh2008An) Farah Sheikh, Anna Raskin, Pao-Hsien Chu, Stephan Lange, Andrea A. Domenighetti, Ming Zheng, Xingqun Liang, Tong Zhang, Toshitaka Yajima, Yusu Gu, Nancy D. Dalton, Sushil K. Mahata, Gerald W. Dorn, Joan Heller-Brown, Kirk L. Peterson, Jeffrey H. Omens, Andrew D. McCulloch, and Ju Chen. An fhl1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. Journal of Clinical Investigation, 118(12):3870–3880, December 2008. URL: http://dx.doi.org/10.1172/jci34472, doi:10.1172/jci34472. This article has 204 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci34472)

[7. (Gueneau2009Mutations) Lucie Gueneau, Anne T. Bertrand, Jean-Philippe Jais, Mustafa A. Salih, Tanya Stojkovic, Manfred Wehnert, Maria Hoeltzenbein, Simone Spuler, Shinji Saitoh, Annie Verschueren, Christine Tranchant, Maud Beuvin, Emmanuelle Lacene, Norma B. Romero, Simon Heath, Diana Zelenika, Thomas Voit, Bruno Eymard, Rabah Ben Yaou, and Gisèle Bonne. Mutations of the fhl1 gene cause emery-dreifuss muscular dystrophy. The American Journal of Human Genetics, 85(3):338–353, September 2009. URL: http://dx.doi.org/10.1016/j.ajhg.2009.07.015, doi:10.1016/j.ajhg.2009.07.015. This article has 193 citations.](https://doi.org/10.1016/j.ajhg.2009.07.015)